HC Wainwright Has Bearish Forecast for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at HC Wainwright dropped their FY2025 earnings per share estimates for Larimar Therapeutics in a research report issued to clients and investors on Monday, December 16th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($1.77) for the year, down from their prior forecast of ($1.57). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($1.99) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.13. During the same quarter in the prior year, the business posted ($0.21) earnings per share.

A number of other research firms also recently weighed in on LRMR. Robert W. Baird initiated coverage on Larimar Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price target on the stock. Wedbush assumed coverage on Larimar Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 target price on the stock. Baird R W upgraded Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Oppenheimer started coverage on Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 price target for the company. Finally, William Blair reissued an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 19th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.43.

Larimar Therapeutics Stock Performance

Shares of LRMR stock opened at $3.98 on Thursday. The firm’s 50 day moving average price is $6.97 and its two-hundred day moving average price is $7.65. Larimar Therapeutics has a 52-week low of $3.01 and a 52-week high of $13.68. The stock has a market cap of $253.95 million, a PE ratio of -3.46 and a beta of 0.86.

Hedge Funds Weigh In On Larimar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LRMR. Janus Henderson Group PLC raised its holdings in Larimar Therapeutics by 27.2% during the 3rd quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after buying an additional 1,189,467 shares during the period. Driehaus Capital Management LLC increased its position in shares of Larimar Therapeutics by 20.8% during the second quarter. Driehaus Capital Management LLC now owns 1,314,106 shares of the company’s stock worth $9,527,000 after acquiring an additional 225,879 shares in the last quarter. Quest Partners LLC increased its position in shares of Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock worth $60,000 after acquiring an additional 5,796 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Larimar Therapeutics by 37.7% during the second quarter. Point72 Asset Management L.P. now owns 603,581 shares of the company’s stock worth $4,376,000 after acquiring an additional 165,181 shares during the period. Finally, Millennium Management LLC lifted its position in Larimar Therapeutics by 30.2% in the 2nd quarter. Millennium Management LLC now owns 1,018,135 shares of the company’s stock valued at $7,381,000 after acquiring an additional 235,865 shares in the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.